Table 3.
Number of patients (n) | HLA | Allele frequency [%] | Significance level (p) | Authors | |
---|---|---|---|---|---|
Study group | Control group | ||||
RAS (31) C (961) Brazil |
A33 B35 B81 |
19.4* 48.4* 6.5* |
6.5* 21.2* 0.8* |
0.016* < 0.001* 0.036* |
Wilhelmsen et al.,2009 [48] |
RAS (101) C (97) Turkey |
B51 |
45.5 |
46.3 |
0.905 |
Özdemir et al., 2009 [49] |
BD (100) C (97) Turkey |
63.0* |
46.3* |
0.019* |
||
BD (32) C (310) China |
DRw8 |
37.5* |
9.7* |
< 0.0001* |
Sun et al.,2001 [18] |
RAS (20) Finland |
B12 | 25.0 | - | - | Malmström et al.,1983 [51] |
RAS (20) C (100) UK |
45.0* |
22.0* |
< 0.05* |
Lehner et al., 1982 [52] | |
BD (60) C (100) UK |
46.6* |
22.0* |
< 0.01* |
||
RAS (17) C (70) UK |
DR7 |
11.8 |
17.1 |
NS |
|
BD (51) C (70) UK |
39.2* |
17.1* |
< 0.01* |
||
RAS (26) C (84) Italy |
DR7 B5 |
61.5* 0* |
21.4* 27.3* |
< 0.0025* < 0.04* |
Gallina et al., 1985 [53] |
Statistically significant differences